Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
MIST
vs
S&P 500
MIST
S&P 500
Over the past 12 months, MIST has underperformed S&P 500, delivering a return of -57% compared to S&P 500's +11% growth.
Stocks Performance
MIST vs S&P 500
Performance Gap
MIST vs S&P 500
Performance By Year
MIST vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Milestone Pharmaceuticals Inc
Glance View
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing etripamil, a nasal spray medicine designed to treat sudden episodes of fast heart rhythm. Its lead use is for patients with paroxysmal supraventricular tachycardia, a condition that can cause abrupt, uncomfortable bursts of rapid heartbeat. The company’s work centers on turning a hospital-style treatment into something a patient can use quickly outside the hospital. The company does not sell a broad range of drugs. Its business is built around one main product candidate and the clinical, regulatory, and commercialization steps needed to bring it to market. If approved and launched, Milestone would make money by selling the medicine through the pharmaceutical distribution system, typically through prescriptions written by doctors and filled by pharmacies or specialty channels. What makes Milestone different is its focus on a fast, easy-to-use nasal delivery format for heart rhythm problems that are often handled in emergency rooms or with more cumbersome treatments. That gives it a niche role in the cardiovascular care market: trying to move treatment of sudden arrhythmia episodes into a simpler outpatient setting for patients and cardiologists.
